cns long case, short case rs, dcld, moderate splenomegy Fibrothorax Abdomen - exam cases: FINAL LIST *_DCLD_* *CONFIRMED cases:* 1.) Ward 134 - M4 Arumugam DCLD/ moderate ascites 2.) Ward 134 - M4 Manikandan 48 DCLD/ moderate ascites 3.) Ward 125 - M2 Shanmugam 55/M Dcld with moderate ascites 4.) Ward 122 - M7 Rajamanickam 58/M DCLD /PHTN /Moderate ascites 5.) Ward 122 - M7 Paulraj 43/m DCLD/ HRS/ HE1 6.) Ward 125 - M2 Venkatesan 47/M Dcld/ moderate ascites *BACKUP cases:* 7.) Ward 113 - M1 Sivakumar 46/ M DCLD with PHTN 8.) Ward 134 - M4 Rajendran 60 Cardiac cirrhosis/ CAD Massive ascites 9.) 142 ward - M6 Palani DCLD/ moderate ascites Hepatology male wards 10.) Aravind 44/m Dcld with phtn/ mod ascites 11.) Prashanth 50/M Dcld with phtn/cam - DILI/moderate ascites 12.) Sreekanth 37/M Dcld with phtn/ mod ascites 13.) Hemachandran 31/M (backup) Dcld with phtn/ moderate ascites —————-x————— *_ORGANOMEGALY_* *CONFIRMED cases:* 123 ward - M6 1.) Prema - massive splenomegaly Hematology 143 ward 2.) Nethra - AIHA/ moderate splenomegaly *BACKUP cases:* 3.) Hemat 143 ward Revathi 37 B ALL/ splenomegaly 4.) 144 ward Med onco case Sakthivel 57 DLBCL/ splenomegaly Thank you sir Good afternoon sir/ maam *Provisional RS cases:* *Confimed cases:* 2 cases 1) Sadayanthi 70/M 113 ward - M1 unit *Diagnosis:* Bronchiectasis/ old ptb / mat/ hfref 30% *Findings:* * Clubbing+ grade 3 * Fine crepts right suprascapular and interscapular regions * B/l wheeze 2) Chinna ponnu 131 ward - M1 unit *Diagnosis:* AECOPD/Multiple lung patchy condolidations /old ptb *Findings:* * Left > Right bronchial breath sounds *Backup cases:* 1) Aruldoss 113 ward - M1 unit *Diagnosis:* pneumonia *Findings:* * Right ia/Im bbs with crepts * Clubbing present 2.Ravi 62/M 134 ward - M4 unit *Diagnosis:* Left Fibrothorax/ PTB sequelae/severe AS / s/p AVR / SHTN *Findings:* * Tracheal shift to Right side * Decreased AE in left hemithorax * Bilateral supraclavicular hollowing 3. Anadharaj 42/M R mod pleural effusion/ Volume overload state/ cad/ckd Finding ; R side decreased air entry Thankyou sir/ mam Good evening sir CNS Case list - 01.06.26 *134* *(M4)* 1.Selvaraj 70/M Acute CVA- hemorrhagic L GC Bleed/R facial palsy/SHTN/T2DM R UL & LL 1+/5 Decreased tone/Babinski + R UMN 7th S(-) A(-) 2.Kumar 56/M Acute CVA- non hemorrhagic/? Malignancy related L UL& LL 1+/5 Decreased tone/Babinski neg L UMN 7th S(-) A(-) *145* *(M3)* 3.Jayavel 54/M Acute CVA- ischemic Recurent CVA/SHTN L UL&LL 1+/5 Decreased tone/Babinski (+) S(-) A(-) *123* *(M6)* 4.Mohammad Mukith Ahmed 52/M Acute CVA-L hemiparesis/Recurrent CVA-?CVT/non hemorrhagic L UL & LL 2+/5 N tone/Babinski neg S(-) A(-) *123* *(M6)* 5.Manonmani 60/F Ca Vagina S/P CRRT -CNS mets R UL& LL 2+/5 N tone/Babinski neg S(-) A(-) *123* *(M6)* 6.Uma 56/F Acute CVA -L hemiparesis c L facial palsy L UL&LL 2+/5 Decreased tone/Babinski positive L UMN 7th *123* *(M6)* 7.Dhanalakshmi 50/F Acute CVA-R GC L Hemiparesis infarct L UL&LL 2+/5 decreased tone/Babinski + L UMN 7th *N2 ward* Neurology 8.Meera Sahiba 52/F Acute ischemic stroke/Rt atonic hemiparesis R UMN facial palsy R UL&LL 3/5 Tone N/Babinski (-) S(-) A(-) *125* *M2* 9.Sukumar 55/M Acute Hemorrhagic CVA-SHTN R UL 1+/5 LL 3+/5 Tone N/Babinski + S(-) A(-) 10. Ward 121 M7 Sathyavani Acute ischemic stroke/ L hemiparesis / T2Dm/SHTN/ cad Power R 5/5 L 4/5 Tone increased in L side Plantar left withdrawal right flexor Dtr exaggerated Thank you sir Good morning sir Verified Cvs cases CTS -2nd floor 1) Amudha 52/f Rhd severe MS Mid diastolic murmur + New cases 113 1) Mohammed ishque 61/m Moderate AS/AR 2) Vignesh 24/m Severe MS 131 1)Vennila 41/f Moderate AS/ moderate Ms 2) Maheshwari 40/f Severe Ms M7 Visalakshi 53/f Severe MR With mild MS
Asking for Preferences
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Here is a breakdown of everything covered above:
What This Reference Covers
4 Systems, 30+ Cases organized and explained:
ABDOMEN (Long Case) - DCLD
- 13 DCLD cases tabulated with ward/diagnosis
- Full clinical examination sequence (hands → face → chest → abdomen → legs)
- Child-Pugh & MELD scoring tables
- HRS management (Terlipressin + Albumin), HE grading, SBP criteria
- Special note on Cardiac Cirrhosis (Rajendran - higher protein ascites, raised JVP)
ABDOMEN (Short Case) - Organomegaly
- 4 splenomegaly cases with etiology-specific approach
- Grading criteria, palpation technique, differentials by size
- AIHA (Warm vs Cold), DLBCL (R-CHOP), B-ALL specifics
RESPIRATORY (Short Case)
- Fibrothorax (Ravi) - trachea pulled towards affected side, this distinguishes it from effusion (pushed away)
- Bronchiectasis with clubbing and post-TB pattern
- BBS consolidation findings
CNS (Long/Short Case) - Stroke
- All 10 CVA cases tabulated with laterality, power, Babinski, facial palsy
- UMN pattern confirmation, lesion localization
- Special cases: CVT (Mukith Ahmed), CNS mets (Manonmani)
CVS (Short Case) - Valvular Disease
- All 6 cases including combined lesions
- Auscultation position and findings for each valve lesion
- Severity criteria for each (MVA <1 cm², AVA <1 cm², peak gradient >40 mmHg)
- BMV candidacy (Wilkins score <8) for severe MS cases
Let me know if you want deeper preparation on any specific case or system!
Generate complete case presentation for CNS cases alone 1 by 1 with summary diagnosis discussion investigation management and viva questions and answers, examination procedure and postive findings
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
All 10 CNS cases are now fully covered. Here is what was generated for each case:
What Each Case Contains
Every case was built with 7 sections:
-
Case Summary - Patient profile, presenting complaint, final diagnosis stated clearly
-
Examination Procedure (Step-by-Step) - General survey → Higher functions → Cranial nerves (with CN VII focus) → Motor system (inspection, tone, power table, reflexes, plantar) → Sensory → Coordination → Gait, with exact instructions on how to perform and present each step
-
Positive Findings Summary - Table of all positive signs with their significance
-
Diagnosis Discussion - Pathophysiology explaining why the findings occur, lesion localization, differentials specific to that case
-
Investigations - Table with expected findings and rationale
-
Management - Acute phase and secondary prevention, with drug doses
-
Viva Questions & Answers - 3-7 targeted Q&As per case covering the most commonly asked examiner topics
Special Highlights by Case
| Case | What Makes It Unique |
|---|---|
| Selvaraj | Hemorrhagic ICH - Charcot's artery, ICH score, why no steroids |
| Kumar | Trousseau syndrome - malignancy + stroke connection |
| Jayavel | Recurrent CVA - CHANCE trial, secondary prevention targets |
| Mukith Ahmed | CVT - MRV, empty delta sign, why anticoagulate in hemorrhagic CVT |
| Manonmani | CNS Mets - dexamethasone, WBRT vs SRS, leptomeningeal Ca |
| Uma + Dhanalakshmi | Classic MCA territory - UMN facial palsy pathway explained |
| Meera Sahiba | Diaschisis - why acute stroke is flaccid, not spastic |
| Sukumar | Asymmetric UL > LL - somatotopic organization of IC |
| Sathyavani | Triple risk factors - withdrawal plantar in DM neuropathy, ABCD2 score |
Respiratory system 1)Harish Left moderate pleural effusion 2)veera 37/M Left fibrocavity/old PTB 3)Ravi 62/M Left fibrothorax/PTB sequele/SHTN 4)Gnanasundari Left fibrothorax 5) Arul dass Left lower lobe bronchiectasis Clubbing
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
All 5 RS cases are complete. Here is what was covered for each:
Case-by-Case Summary
Case 1 - Harish | Left Moderate Pleural Effusion
- Full step-by-step examination: inspection → trachea palpation → expansion → TVF → percussion (with Traube's, Grocco's, Garland's triangle explained) → auscultation
- Light's criteria table with sensitivity/specificity
- Transudate vs exudate causes table + additional fluid analysis clues (ADA, pH, cytology)
- Thoracocentesis technique + safe triangle
- 7 viva Q&As including re-expansion pulmonary edema and empyema vs parapneumonic
Case 2 - Veera 37/M | Left Fibrocavitary/Old PTB
- Why upper lobe involvement, amphoric breath sounds, post-tussive crackles
- Pathophysiology of cavity formation, all cavity complications (Rasmussen's aneurysm, aspergilloma, pneumothorax)
- ATT regimen table with drug doses and toxicities
- GeneXpert advantages, MDR-TB regimen
- 6 viva Q&As
Case 3 - Ravi 62/M | Left Fibrothorax + SHTN
- The critical fibrothorax vs effusion comparison table (most asked viva topic)
- Bilateral supraclavicular hollowing explained
- PFT restrictive pattern, decortication indications
- 5 viva Q&As
Case 4 - Gnanasundari | Left Fibrothorax
- Complete examination presentation script (ready to say verbatim in front of examiner)
- Confirmation on USG vs CT
- Bilateral fibrothorax discussion
Case 5 - Aruldoss | LLL Bronchiectasis + Clubbing
- Clubbing examination technique (Schamroth's window test) + grading table
- Reid classification (cylindrical/varicose/saccular)
- Causes table, why lower lobe, pathophysiology of clubbing (VEGF/PDGF)
- HRCT signet ring sign, Kartagener's, ABPA
- Azithromycin evidence (EMBRACE trial), why DNase NOT used in non-CF bronchiectasis
- 7 viva Q&As
Bonus - Master Comparison Table
Final summary table comparing all 4 patterns (effusion/fibrothorax/fibrocavitary/bronchiectasis) side-by-side for rapid revision.
Prepare short case sheets with summary and postive history and positive findings diagnosis and investigation management and viva for the rs cases
Here are all 5 RS short case sheets in compact, exam-ready format:
RS SHORT CASE SHEETS - EXAM READY
SHORT CASE SHEET 1
SADAYANTHI, 70/M | Ward 113 - M1 Unit
ONE-LINE DIAGNOSIS
Bronchiectasis with old PTB sequelae + Multidrug-Resistant/MAT (Multiply-Affected Tuberculosis) + Heart Failure with Reduced Ejection Fraction (HFrEF 30%)
POSITIVE HISTORY (What to elicit)
| Symptom | Expected in this Patient |
|---|---|
| Chronic productive cough | Longstanding, daily, copious mucopurulent sputum (>30 mL/day) |
| Hemoptysis | Episodes of blood-stained sputum (bronchiectasis + old PTB cavities) |
| Breathlessness | Progressive, on exertion, orthopnea, PND (HFrEF component) |
| Wheeze | Bilateral, exertional (airflow obstruction from old PTB + bronchiectasis) |
| Old TB history | Prior ATT (duration, completion, defaulter?) |
| Recurrent chest infections | Multiple hospitalizations for exacerbations |
| Ankle swelling | Bilateral (HFrEF - left heart failure → right heart involvement) |
| Past cardiac history | Diagnosed HFrEF 30% - any prior MI, CAD, valvular disease? |
Risk factors to ask: Smoking, DM, SHTN, prior ATT, alcohol (TB risk), occupational dust exposure
POSITIVE FINDINGS
| System | Finding | Significance |
|---|---|---|
| Hands | Clubbing Grade 3 | Chronic suppurative lung disease (bronchiectasis) |
| Peripheral cyanosis | Chronic hypoxia | |
| Vitals | Tachypnea, tachycardia | Active respiratory compromise |
| Trachea | Central or mildly deviated | Bilateral disease - no significant shift |
| Chest expansion | Decreased bilaterally | Bilateral disease + HFrEF (pulmonary congestion) |
| TVF | Increased RIGHT suprascapular + interscapular | Consolidation/fibrosis in right upper lobe (post-PTB) |
| Percussion | Dull RIGHT upper zone | Fibrosis/consolidation |
| Breath sounds | Fine crepts right suprascapular + interscapular | Post-PTB fibrosis + bronchiectasis |
| Bilateral wheeze | Airflow obstruction | |
| CVS | S3 gallop possible | HFrEF |
| Bilateral basal crepts | Pulmonary edema (HFrEF contribution) | |
| Raised JVP | Right heart failure/cor pulmonale | |
| Bilateral pitting edema | Right heart failure |
Exact documented findings:
- Clubbing Grade 3
- Fine crepts: Right suprascapular + right interscapular regions
- Bilateral wheeze
DIAGNOSIS
Primary: Bronchiectasis (Post-PTB) with active infective exacerbation
Coexisting conditions:
- Old PTB sequelae (fibrosis in right upper lobe)
- MAT (Multiply Affected Tuberculosis = recurrent/retreatment TB)
- HFrEF EF 30% (likely secondary to chronic cor pulmonale OR independent ischemic/non-ischemic cardiomyopathy)
Why bronchiectasis here:
- Old PTB → airway damage → dilated bronchi → impaired clearance → recurrent infection → progressive dilatation
- Right upper lobe most commonly affected by PTB
- Fine crepts + clubbing + right upper zone disease = classic post-TB bronchiectasis picture
INVESTIGATIONS
| Investigation | Expected Finding |
|---|---|
| HRCT Chest (Gold standard) | Signet ring sign (broncho-arterial ratio >1.5), tram-track lines, right upper lobe fibrosis, calcified nodes |
| CXR PA | Ring shadows, tram lines, right upper zone opacity/fibrosis, cardiomegaly (HFrEF) |
| Sputum AFB × 3 + GeneXpert | Exclude active TB, detect resistance |
| Sputum C&S | Pseudomonas, Haemophilus, Staph aureus (common colonizers) |
| 2D Echo | EF 30% (HFrEF), LV dysfunction, wall motion abnormality |
| BNP/NT-proBNP | Elevated in HFrEF |
| PFT (Spirometry) | Obstructive or mixed pattern; FEV1/FVC <0.7 |
| ABG | Hypoxemia (PaO2 low), possible type 2 respiratory failure (↑PaCO2) |
| CBC | Neutrophilia (exacerbation), anemia of chronic disease |
| Serum IgG, IgA, IgM | Immunodeficiency as contributing cause |
| Blood culture | If sepsis suspected |
| ECG | P pulmonale, LVH, old MI changes |
MANAGEMENT
Bronchiectasis exacerbation:
- Oxygen: maintain SpO2 94-98% (88-92% if chronic CO2 retainer)
- Antibiotics: Amoxicillin-Clavulanate 875/125 mg BD × 14 days (or Ciprofloxacin 500 mg BD if Pseudomonas)
- Chest physiotherapy + postural drainage
- Nebulized salbutamol + ipratropium (for wheeze)
- Long-term Azithromycin 250 mg 3×/week (EMBRACE trial - reduces exacerbations)
HFrEF (EF 30%) management:
- Furosemide 40 mg OD (diuresis)
- Carvedilol 3.125 mg BD titrating up (β-blocker for HFrEF)
- Ramipril/Perindopril (ACE inhibitor) or Sacubitril-Valsartan (ARNi)
- Spironolactone 25 mg OD (MRA)
- SGLT2 inhibitor (Dapagliflozin 10 mg OD) - reduces HFrEF mortality
- Fluid restriction 1.5 L/day, salt restriction, daily weight monitoring
Old PTB/MAT:
- If active TB: ATT as per sensitivity pattern
- If MAT with prior treatment: GeneXpert + LPA (Line Probe Assay) for 1st/2nd line resistance
VIVA Q&A
Q1. Why does the patient have bilateral wheeze?
A: Two mechanisms contribute: (1) Airway obstruction from bronchiectasis and post-PTB fibrosis causing airway distortion and secretion-related obstruction; (2) Pulmonary congestion from HFrEF causing peribronchial edema → cardiac wheeze (cardiac asthma). Bilateral wheeze = treat both conditions.
Q2. What is the connection between HFrEF and bronchiectasis?
A: Chronic hypoxia from bronchiectasis → pulmonary vasoconstriction → pulmonary hypertension → cor pulmonale (right heart failure) → can appear as HFrEF clinically. Alternatively, patient may have concurrent ischemic cardiomyopathy (CAD as comorbidity). BNP and Echo differentiate.
Q3. What is MAT (Multiply-Affected Tuberculosis)?
A: Refers to patients with multiple episodes of tuberculosis - either relapse (same strain), re-infection (new strain), or treatment failure. At high risk for drug resistance. Mandatory GeneXpert + culture with DST before starting retreatment.
Q4. What is fine vs coarse crepts? What is the significance here?
A: Fine crepts (late inspiratory) = alveolar disease - pulmonary fibrosis (post-PTB), pulmonary edema. Coarse crepts (early/mid-inspiratory) = larger airway secretions - bronchiectasis. In Sadayanthi: fine crepts at suprascapular/interscapular = right upper lobe post-TB fibrosis (not active bronchiectasis crepts). The wheeze indicates the bronchiectatic/obstructive component.
Q5. What is the significance of EF 30% clinically?
A: EF 30% = severely reduced (normal ≥55%). At this level: high risk of sudden cardiac death (ICD indicated if on optimal medical therapy), significant risk of cardioembolic stroke, severe heart failure symptoms (NYHA III-IV). SGLT2 inhibitor + ARNI + beta blocker + MRA = quadruple therapy (2023 ESC guidelines).
SHORT CASE SHEET 2
CHINNA PONNU | Ward 131 - M1 Unit
ONE-LINE DIAGNOSIS
Acute Exacerbation of COPD (AECOPD) with Multiple Lung Patchy Consolidations + Old PTB Sequelae
POSITIVE HISTORY
| Symptom | Expected |
|---|---|
| Chronic cough | Longstanding (>3 months, >2 consecutive years = chronic bronchitis definition) |
| Increased sputum production | Recent worsening, change in color (yellow/green = infective exacerbation) |
| Worsening breathlessness | Acute on chronic - baseline dyspnea worsening over days |
| Wheeze | Chronic, worsening acutely |
| Old TB history | Prior ATT, completion status |
| Smoking history | Pack-year history (most common cause of COPD) |
| Previous similar episodes | Prior AECOPD admissions, ICU stays, intubation history |
| Sputum color change | Clear → yellow/green (Anthonisen criteria for antibiotic use) |
Precipitants of AECOPD to ask: URTI (viral - most common 80%), bacterial (H. influenzae, Moraxella, Streptococcus pneumoniae), stopped inhalers, air pollution, cold weather, PE (non-infective)
POSITIVE FINDINGS
| Finding | Side | Significance |
|---|---|---|
| Tachypnea | - | Respiratory distress |
| Accessory muscle use | - | Increased work of breathing |
| Barrel chest (if established COPD) | - | Air trapping, hyperinflation |
| Trachea | Central | Bilateral disease |
| TVF | Increased LEFT > RIGHT | Consolidation (patchy) bilateral |
| Percussion | Dull LEFT and right lower zones | Consolidations |
| Hyperresonant upper zones | Air trapping (COPD component) | |
| Breath sounds | Left > Right Bronchial Breath Sounds | Left-dominant consolidation |
| Coarse crackles bilateral | Secretions in consolidated segments | |
| Wheeze bilateral | COPD/airflow obstruction | |
| Signs of cor pulmonale | Raised JVP, edema | If chronic COPD |
Documented finding: Left > Right bronchial breath sounds (consolidation more prominent on left)
DIAGNOSIS
AECOPD = Acute worsening of respiratory symptoms (dyspnea, cough, sputum) beyond normal day-to-day variation requiring change in management (Anthonisen 1987 / GOLD definition)
Consolidation superimposed on COPD = likely community-acquired pneumonia triggering AECOPD
Anthonisen Criteria for infective AECOPD (antibiotic use justified if ≥2):
- Increased dyspnea
- Increased sputum volume
- Increased sputum purulence
COPD GOLD Staging (by FEV1%):
| GOLD Grade | FEV1 % predicted |
|---|---|
| I (Mild) | ≥80% |
| II (Moderate) | 50-79% |
| III (Severe) | 30-49% |
| IV (Very Severe) | <30% |
Bronchial Breath Sounds (BBS) over consolidation:
- Consolidation = solidified lung (alveoli filled with fluid/pus)
- Solid lung transmits bronchial sounds directly to chest wall
- BBS character: HIGH-pitched, hollow, tubular; inspiratory and expiratory are equal; pause between phases absent
- Associated: Bronchophony, Aegophony (e→a change), Whispering pectoriloquy
INVESTIGATIONS
| Investigation | Expected Finding |
|---|---|
| CXR PA | Bilateral patchy opacities (consolidations), hyperinflated lungs, flat diaphragm (COPD background), old PTB fibrosis |
| ABG (most important in AECOPD) | Type 1 RF: PaO2↓, PaCO2 normal; or Type 2 RF: PaO2↓, PaCO2↑ (hypercapnic) - guides oxygen therapy and NIV need |
| Spirometry | FEV1/FVC <0.70 post-bronchodilator (COPD confirmation); NOT done during acute exacerbation |
| Sputum C&S | Pathogen identification, guide antibiotics |
| GeneXpert (sputum) | Exclude active TB in old PTB patient |
| CBC | Neutrophilia (bacterial), lymphocytosis (viral), polycythemia (chronic hypoxia) |
| Serum electrolytes | Hypokalemia (salbutamol effect), hyponatremia |
| CRP, Procalcitonin | Bacterial vs viral exacerbation |
| ECG | P pulmonale, right heart strain, arrhythmia |
| BNP | If CCF contributing to consolidation |
| CTPA | If PE suspected as non-infective AECOPD trigger |
MANAGEMENT
Acute Phase (AECOPD management - GOLD 2024):
1. Controlled Oxygen Therapy:
- Target SpO2: 88-92% (NOT high-flow - risk of hypercapnic respiratory failure due to Haldane effect)
- Start at 24-28% Venturi mask
- Recheck ABG after 30-60 minutes
2. Short-Acting Bronchodilators (First line):
- Salbutamol 2.5 mg nebulized 4-6 hourly
- Ipratropium 0.5 mg nebulized 6-8 hourly
- Can combine in same nebulizer
3. Systemic Corticosteroids:
- Prednisolone 40 mg OD × 5 days (REDUCE trial - 5 days non-inferior to 14 days)
- Reduces treatment failure, shortens recovery
4. Antibiotics (if Anthonisen ≥2 criteria or purulent sputum):
- Mild-Moderate: Amoxicillin-Clavulanate 875/125 mg BD OR Doxycycline 100 mg BD × 5-7 days
- Severe (ICU/Pseudomonas risk): Piperacillin-Tazobactam + Ciprofloxacin IV
5. Non-Invasive Ventilation (NIV) - if pH <7.35 and PaCO2 >45 mmHg:
- BiPAP: IPAP 12-16 cmH2O, EPAP 4-6 cmH2O
- First-line for hypercapnic respiratory failure in AECOPD
- Avoid intubation if possible
6. Treat Consolidation (pneumonia-triggered AECOPD):
- CAP: Ceftriaxone 1g IV OD + Azithromycin 500 mg IV OD (atypical coverage)
- Or Levofloxacin 750 mg IV OD (monotherapy for CAP)
Maintenance (Discharge - GOLD guidelines):
- ICS + LABA (e.g., Budesonide/Formoterol) if frequent exacerbations
- LAMA (Tiotropium 18 mcg OD) - reduces exacerbation frequency
- Pulmonary rehabilitation
- Smoking cessation counseling + varenicline/NRT
- Influenza vaccine + Pneumococcal vaccine
VIVA Q&A
Q1. Why target SpO2 88-92% in COPD, not 94-98%?
A: In chronic hypercapnic COPD, the central respiratory drive relies on hypoxic stimulus (hypoxic drive) rather than CO2 levels (which are chronically elevated). Giving high-flow O2 abolishes this hypoxic drive → hypoventilation → CO2 retention → hypercapnic respiratory failure. Additionally, high O2 causes release of CO2 from oxyhemoglobin (Haldane effect) and V/Q mismatch worsening. Target 88-92% is safe.
Q2. What are the Anthonisen criteria?
A: Three cardinal features of infective AECOPD: (1) increased dyspnea, (2) increased sputum volume, (3) increased sputum purulence. Type I (all 3) = antibiotics clearly beneficial. Type II (any 2) = antibiotics likely beneficial. Type III (any 1) = antibiotics uncertain benefit unless purulence is present.
Q3. What is the difference between consolidation and collapse?
A: Consolidation = alveoli filled with fluid/pus/cells (no volume loss). Collapse (atelectasis) = alveoli empty, lung deflated (volume loss). Consolidation: bronchial BS, dull percussion, NO tracheal shift. Collapse: bronchial BS, dull percussion, trachea pulled TOWARD (volume loss). Both give BBS, but collapse causes ipsilateral tracheal shift.
Q4. What is whispering pectoriloquy?
A: Ask patient to whisper "99" - normally whispered sounds are inaudible over peripheral lung. Over consolidation: whispered sounds are clearly transmitted (enhanced) = positive whispering pectoriloquy. Same mechanism as aegophony (e→a change) and bronchophony - consolidated lung transmits high-frequency sounds better than aerated lung.
Q5. What is NIV failure? When do you intubate?
A: NIV failure indicators: worsening pH (<7.25) despite NIV × 1-2 hours, SpO2 not improving, hemodynamic instability, altered consciousness (GCS <8), inability to protect airway, copious secretions. If NIV fails → invasive mechanical ventilation (intubation).
Q6. How do you differentiate AECOPD from cardiac asthma?
A: Both present with acute wheeze and breathlessness. Cardiac asthma (pulmonary edema): orthopnea, PND, S3 gallop, raised JVP, bilateral basal fine crepts, pink frothy sputum, BNP elevated, CXR shows perihilar bat-wing pattern + Kerley B lines. AECOPD: smoking history, chronic cough, barrel chest, pursed lip breathing, prolonged expiration, hyperinflation on CXR, low BNP (unless cor pulmonale).
SHORT CASE SHEET 3 (Backup)
ARULDOSS | Ward 113 - M1 Unit
ONE-LINE DIAGNOSIS
Community-Acquired Pneumonia (Right Lower Lobe / Right Infra-axillary + Interscapular) with Clubbing (? Underlying Bronchiectasis)
POSITIVE HISTORY
| Symptom | Expected |
|---|---|
| Fever | Acute onset, high grade (pneumococcal: abrupt; atypical: gradual) |
| Cough | Initially dry, then productive of rusty/mucopurulent sputum |
| Pleuritic chest pain | Right-sided, sharp, worsens with breathing/cough (pleural involvement) |
| Breathlessness | Proportional to size of consolidation |
| Rigor | Single rigor = pneumococcal pneumonia (classical) |
| Clubbing history | Long-standing - pre-existing lung disease (bronchiectasis, old PTB) |
| Recent URTI | Viral prodrome preceding pneumonia |
| Aspiration risk | Alcohol, epilepsy, dysphagia (aspiration pneumonia lower lobe) |
POSITIVE FINDINGS
| Finding | Side | Significance |
|---|---|---|
| Clubbing | Present | Pre-existing bronchiectasis/old PTB (NOT from acute pneumonia) |
| Fever | - | Infective etiology |
| Tachypnea | - | Respiratory distress (CURB-65 scoring) |
| Trachea | Central | No significant volume shift (consolidation = no volume loss) |
| Expansion | Decreased RIGHT lower zone | Consolidation restricts movement |
| TVF | Increased RIGHT IA/IM | Consolidation transmits vibration better |
| Percussion | Dull RIGHT infra-axillary/interscapular | Consolidated lung = solid, dull |
| Breath sounds | Right IA/IM Bronchial Breath Sounds | Consolidation (documented) |
| Crepts present RIGHT | Secretions in consolidating alveoli | |
| Pleural rub (possible) | Pleuritis adjacent to consolidation |
Documented: Right IA/IM BBS + crepts + Clubbing
IA = Infra-axillary | IM = Infra-mammary → Right lower lobe consolidation
DIAGNOSIS
Right Lower Lobe Community-Acquired Pneumonia
Severity assessment - CURB-65 Score:
| Parameter | Score |
|---|---|
| Confusion (AMT ≤8 or new disorientation) | 1 |
| Urea >7 mmol/L (>19 mg/dL) | 1 |
| Respiratory rate ≥30/min | 1 |
| BP: systolic <90 or diastolic ≤60 | 1 |
| 65 years or older | 1 |
- Score 0-1: Outpatient
- Score 2: Hospital admission
- Score 3-5: ICU/HDU consideration
Common organisms by presentation:
| Presentation | Organism |
|---|---|
| Abrupt onset, single rigor, rusty sputum | S. pneumoniae (classic) |
| Gradual, dry cough, headache, diarrhea | Mycoplasma pneumoniae (atypical) |
| Gram-negative, elderly, alcoholic | Klebsiella (right upper lobe - red currant jelly sputum) |
| Post-influenza, skin infection | Staphylococcus aureus |
| Legionella | Air-conditioner exposure, hyponatremia |
| Aspiration | Anaerobes, lower lobe, foul sputum |
| Cavitating pneumonia | Klebsiella, Staph aureus, TB |
INVESTIGATIONS
| Investigation | Expected Finding |
|---|---|
| CXR PA | Homogeneous opacity right lower zone + air bronchograms (consolidation), no volume loss, no tracheal shift |
| HRCT Chest | If complication suspected (cavitation, empyema, abscess) |
| CBC | Neutrophilia + raised CRP (bacterial); lymphocytosis (viral/atypical) |
| Blood culture × 2 | Bacteremia in 25-30% pneumococcal CAP |
| Sputum Gram stain + C&S | Identify organism, guide therapy |
| Sputum GeneXpert | If TB not excluded (especially with clubbing) |
| Urinary antigen | Legionella antigen, Pneumococcal antigen |
| Mycoplasma IgM | Atypical CAP |
| Serum electrolytes | Hyponatremia (Legionella, SIADH in severe CAP) |
| ABG | If SpO2 <90% or CURB-65 ≥3 |
| LFT | Elevated in Legionella, drug toxicity |
| Procalcitonin | >0.25 mcg/L = bacterial; guides antibiotic duration |
MANAGEMENT
Mild-Moderate CAP (CURB-65 0-2, Ward admission):
- Amoxicillin-Clavulanate 625 mg TDS OR Ceftriaxone 1 g IV OD
-
- Azithromycin 500 mg OD (atypical coverage - MANDATORY in India)
- Duration: 5-7 days (switch IV to oral when afebrile 24-48h, tolerating oral)
Severe CAP (CURB-65 ≥3, ICU):
- Ceftriaxone 2 g IV OD + Azithromycin 500 mg IV OD
- Or Levofloxacin 750 mg IV OD (monotherapy)
- If Pseudomonas risk: Piperacillin-Tazobactam + Levofloxacin
Supportive:
- Oxygen: SpO2 94-98%
- IV fluids if hypotensive
- Antipyretics (Paracetamol 1g QID)
- Physiotherapy: deep breathing, incentive spirometry
- DVT prophylaxis (LMWH) if hospitalized
Clubbing - Address underlying cause:
- HRCT chest post-recovery to evaluate for bronchiectasis
- Sputum AFB/GeneXpert to exclude active TB
VIVA Q&A
Q1. What are the classic CXR features of consolidation vs collapse?
A: Consolidation: homogeneous opacity, air bronchograms, NO volume loss, no tracheal shift. Collapse: opacity + volume loss signs (tracheal shift toward, elevated diaphragm, mediastinal shift, rib crowding, compensatory hyperinflation of other lobe).
Q2. What is an air bronchogram? What does it indicate?
A: Air in bronchi (dark lines) seen against a background of opacified (white) alveoli on CXR/CT. Indicates alveolar consolidation (not collapse) because: in collapse, the bronchi collapse too; in consolidation, bronchi are patent and appear as dark air columns. Presence of air bronchogram confirms consolidation (pneumonia, pulmonary edema, lung cancer rarely).
Q3. What is the CURB-65 score? How does it guide management?
A: Confusion, Urea >7 mmol/L, Respiratory rate ≥30, BP <90/60, age ≥65. Each = 1 point. Score 0-1 = outpatient treatment. Score 2 = admit to ward. Score ≥3 = severe CAP, ICU consideration. 30-day mortality: score 0 = 0.7%, score 5 = 57%.
Q4. Why does pneumococcal pneumonia produce rusty (rust-colored) sputum?
A: S. pneumoniae causes lobar pneumonia with fibrinous exudate in alveoli. Red blood cells from inflamed alveolar capillaries leak into alveolar spaces → hemoglobin degradation → rusty/blood-tinged sputum. A classic pathognomonic feature of pneumococcal CAP.
Q5. Why is clubbing present in this acute pneumonia patient?
A: Clubbing does NOT develop from acute pneumonia (it takes months-years to develop). This patient's clubbing indicates a pre-existing chronic suppurative lung condition - most likely bronchiectasis or old PTB with chronic airway disease. The current admission is for an acute pneumonia SUPERIMPOSED on the underlying condition.
SHORT CASE SHEET 4 (Backup)
RAVI, 62/M | Ward 134 - M4 Unit
ONE-LINE DIAGNOSIS
Left Fibrothorax (Post-PTB Sequelae) + Severe Aortic Stenosis (s/p AVR - Aortic Valve Replacement) + Systemic Hypertension
(This is a complex multi-system short case - RS findings of fibrothorax + incidental CVS findings of post-AVR/severe AS)
POSITIVE HISTORY
RS History:
| Symptom | Expected |
|---|---|
| Breathlessness | Longstanding, progressive restrictive dyspnea (fibrothorax) + effort dyspnea (post-AVR) |
| Old TB history | Previous ATT, complications (empyema → fibrothorax) |
| Pleurisy | History of chest pain during TB episode |
| No fever/sputum currently | Fibrothorax = sequelae, not active infection |
CVS History (AVR/AS):
| Symptom | Expected |
|---|---|
| Exertional syncope | Pre-AVR (Severe AS triad) |
| Angina | Pre-AVR (Severe AS triad) |
| Exertional dyspnea | Pre-AVR + current |
| AVR surgery date | When was surgery? Mechanical or bioprosthetic? |
| Anticoagulation | Warfarin if mechanical AVR - INR monitoring |
| INR monitoring | Target INR 2.5-3.5 for mechanical AVR |
POSITIVE FINDINGS
RESPIRATORY (Primary short case system):
| Finding | Side | Significance |
|---|---|---|
| Tracheal shift | To the RIGHT | Volume loss from left fibrothorax pulling trachea toward left... but documented shift is right - may indicate bilateral disease with right being dominant, or mediastinal effect |
| Supraclavicular hollowing | Bilateral | Old bilateral PTB + cachexia |
| Left hemithorax | Flat/contracted | Volume loss = fibrosis |
| ICS | Narrowed on LEFT | Fibrosis contracts ribs |
| Expansion | Absent LEFT | Rigid fibrotic chest |
| TVF | Absent LEFT | Fibrosis damps vibration |
| Percussion | Stony dull LEFT | Dense fibrotic peel |
| Breath sounds | Decreased/absent LEFT | Trapped lung |
CARDIOVASCULAR (Secondary - observe and mention):
| Finding | Significance |
|---|---|
| Midline sternotomy scar | Previous cardiac surgery (AVR) |
| Mechanical click (S2 area) | Prosthetic valve click (mechanical AVR) |
| Aortic regurgitation murmur (if paravalvular leak) | Post-AVR complication |
| Hypertension on BP measurement | SHTN |
DIAGNOSIS
Left fibrothorax - fibrosis of pleural space, with volume loss and lung entrapment, post-PTB or post-empyema.
Severe AS s/p AVR - patient has already undergone AVR. Severe AS criteria (pre-op): AVA <1 cm², peak gradient >64 mmHg, mean gradient >40 mmHg, jet velocity >4 m/s.
Mechanical vs Bioprosthetic AVR:
| Feature | Mechanical | Bioprosthetic (Tissue) |
|---|---|---|
| Durability | Lifetime | 15-20 years |
| Anticoagulation | Lifelong Warfarin (INR 2.5-3.5) | 3 months only |
| Age preference | <60 years | >65 years |
| Click | Audible mechanical click | Softer sounds |
INVESTIGATIONS
For Fibrothorax:
| Investigation | Finding |
|---|---|
| CXR PA | Left opacification + volume loss, tracheal shift, narrowed ICS, elevated hemidiaphragm |
| HRCT Chest | Calcified fibrous peel, no free fluid, trapped lung |
| PFT | Restrictive pattern (FVC↓, FEV1/FVC normal or ↑) |
| Sputum AFB | Exclude active TB |
For Post-AVR:
| Investigation | Finding |
|---|---|
| 2D Echo | Assess prosthetic valve function, gradient, paravalvular leak, LV function |
| INR | Therapeutic? (target 2.5-3.5 for mechanical AVR) |
| ECG | LVH (pre/post), pacemaker if implanted |
| Blood culture | If prosthetic valve endocarditis suspected |
| CBC | Hemolytic anemia (paravalvular leak → mechanical hemolysis → schistocytes) |
| LDH | Elevated in prosthetic valve hemolysis |
MANAGEMENT
Fibrothorax:
- If symptomatic + viable lung: Decortication (surgical peel removal)
- Contraindicated if active TB → treat TB first, then reassess
- Physiotherapy: diaphragmatic breathing, incentive spirometry
- Oxygen if hypoxic (SpO2 <88% on exertion)
Post-AVR (Mechanical) - ongoing management:
- Warfarin: INR 2.5-3.5 (strict monitoring, lifelong)
- Bridge with LMWH if warfarin interrupted (surgery, procedures)
- Prosthetic valve endocarditis prophylaxis: dental hygiene; antibiotics for high-risk dental procedures (Amoxicillin 2g 1h before)
- Antiplatelet: Aspirin 75-100 mg OD (in addition to warfarin in high-risk)
SHTN:
- Target <140/90 mmHg (or <130/80 if DM/CKD)
- CCB or ARB first-line (ACE inhibitor if LV dysfunction)
- Avoid NSAIDS (affect BP control, warfarin interaction)
VIVA Q&A
Q1. What are the classic symptoms of severe aortic stenosis (the triad)?
A: The triad of severe AS: (1) Exertional syncope - reduced cardiac output with exertion; (2) Angina - increased myocardial oxygen demand + reduced coronary perfusion; (3) Dyspnea/Heart failure - LV outflow obstruction → LV hypertrophy → diastolic dysfunction → pulmonary congestion. Prognosis after symptom onset: syncope = 3-year survival, angina = 5-year, heart failure = 1-2 years without surgery.
Q2. How do you assess a prosthetic valve clinically?
A: Mechanical valve: audible crisp click on auscultation (opening and closing clicks). Assess for: (1) Prosthetic valve endocarditis (fever, new murmur); (2) Paravalvular leak (regurgitation murmur + hemolysis signs: pallor, jaundice, elevated LDH, schistocytes on smear); (3) Valve thrombosis (sudden change in click intensity, reduced gradients on Echo); (4) INR adequacy.
Q3. Why is decortication the treatment for fibrothorax?
A: The fibrous peel encases the lung like a rigid shell, preventing expansion. Decortication removes this peel (cortex), allowing the trapped lung to re-expand. Criteria: symptomatic, viable lung (≥40% predicted function on affected side), patient fit for surgery, no active TB. Early fibrothorax (organizing phase, <6 months) → VATS possible. Chronic calcified fibrothorax → open thoracotomy.
Q4. What INR target for mechanical AVR? What if patient needs emergency surgery?
A: Target INR 2.5-3.5. For emergency surgery: hold warfarin + give Vitamin K 1-2 mg IV slowly + 4-factor PCC (Prothrombin Complex Concentrate) for rapid reversal. Restart anticoagulation within 24-48 hours post-surgery with LMWH bridge until therapeutic warfarin resumed.
SHORT CASE SHEET 5 (Backup)
ANADHARAJ, 42/M | Right Moderate Pleural Effusion + Volume Overload State + CAD + CKD
ONE-LINE DIAGNOSIS
Right Moderate Pleural Effusion - Secondary to Volume Overload State (Cardiorenal Syndrome) in the setting of CAD + CKD
POSITIVE HISTORY
| Symptom | Expected |
|---|---|
| Breathlessness | Acute worsening, orthopnea, PND (CCF/volume overload) |
| Ankle swelling | Bilateral pitting edema (CCF + CKD) |
| Reduced urine output | Oliguria (CKD decompensation / cardiorenal syndrome) |
| Chest pain history | Prior MI or angina (CAD) |
| Known CAD | Stents, CABG, prior MI, current medications |
| Known CKD | Duration, baseline creatinine, renal replacement therapy |
| Weight gain | Rapid weight gain = fluid retention (CCF/CKD) |
| Diet and fluid compliance | Excessive salt/fluid intake triggering decompensation |
POSITIVE FINDINGS
| Finding | Side | Significance |
|---|---|---|
| Bilateral pitting edema | B/L LL | Volume overload (CCF + CKD) |
| Raised JVP | - | Volume overload / right heart failure |
| S3 gallop | Apex | Volume overload / LV dysfunction |
| Cardiomegaly | - | CAD cardiomyopathy |
| Trachea | Deviated LEFT | Pushed away by right effusion |
| Expansion | Decreased RIGHT | Effusion restricts |
| TVF | Absent RIGHT lower | Fluid damps vibration |
| Percussion | Stony dull RIGHT lower-mid | Pleural fluid |
| Breath sounds | Absent RIGHT lower | Fluid blocks sound |
| Fine basal crepts bilaterally | Pulmonary edema (volume overload) | |
| Pallor | - | Anemia of CKD (EPO deficiency) |
| Uremic signs | Sallow complexion, scratch marks | CKD |
| Arteriovenous fistula | Forearm | If on dialysis |
DIAGNOSIS
Right pleural effusion - Likely TRANSUDATE (CCF/CKD/volume overload)
Cardiorenal Syndrome Type 1 or 2:
| Type | Description |
|---|---|
| Type 1 | Acute cardiac failure → acute kidney injury |
| Type 2 | Chronic cardiac failure → CKD (likely in Anadharaj) |
| Type 3 | Acute kidney injury → acute cardiac |
| Type 4 | CKD → chronic cardiac |
| Type 5 | Systemic disease → both |
Why RIGHT-sided effusion in CCF?
- CCF effusions are typically bilateral (70%) or right-sided (right-sided alone 26%) or left (left alone 4%)
- Right-sided predominance: RIGHT hemidiaphragm is more permeable, right hemithorax lower
- Hepatic hydrothorax can contribute from cirrhosis but here volume overload is primary
INVESTIGATIONS
| Investigation | Expected Finding |
|---|---|
| CXR PA | Right moderate effusion + cardiomegaly + Kerley B lines (pulmonary edema) |
| 2D Echo | LV systolic dysfunction (EF reduced from CAD), wall motion abnormality, RV dysfunction, diastolic dysfunction (Grade II-IV) |
| Pleural fluid analysis | Transudate by Light's criteria (protein <25 g/L, LDH low, serum-pleural albumin gradient >1.2 g/dL) |
| Serum BNP / NT-proBNP | Markedly elevated (CCF) - guides diagnosis and treatment response |
| Serum creatinine, eGFR | Elevated (CKD); eGFR <60 mL/min/1.73m² |
| Urine R/E | Proteinuria (nephrotic if CKD nephrotic), casts (renal tubular damage) |
| 24h urine protein | Quantify proteinuria |
| CBC | Normocytic normochromic anemia (CKD - EPO deficiency) |
| Serum electrolytes | Hyperkalemia, hyperphosphatemia, metabolic acidosis (CKD) |
| Serum albumin | May be low (nephrotic component, malnutrition) - affects Light's criteria |
| ECG | Old MI changes, LVH, arrhythmia |
| Troponin | If acute MI triggering decompensation |
| Lipid profile | CAD risk factor management |
| HbA1c | Diabetic CAD/CKD |
MANAGEMENT
Pleural Effusion (Symptomatic - secondary to volume overload):
- Diuresis is primary treatment (NOT thoracocentesis as first step for transudative effusion)
- IV Furosemide 40-80 mg OD or BD (weight-based, monitor UO)
- Spironolactone 25-50 mg OD (potassium-sparing, aldosterone antagonist)
- Target: 0.5-1 kg/day weight loss in volume overload
- Therapeutic thoracocentesis ONLY if: tense effusion causing respiratory distress OR diagnosis uncertain
CCF (Volume Overload) Management:
- Fluid restriction: 1-1.5 L/day
- Salt restriction: <2 g sodium/day
- Daily weight monitoring (>2 kg/2 days = call doctor)
- ACE inhibitor/ARB (caution in CKD - monitor creatinine + potassium)
- Beta blocker (Carvedilol/Bisoprolol) after volume optimization
- ARNI (Sacubitril-Valsartan) if stable HFrEF
CAD Management:
- Dual antiplatelet (if recent stent) or single antiplatelet (Aspirin 75 mg)
- Statin: Atorvastatin 40-80 mg
- Beta blocker, ACEI
- Revascularization if ischemic trigger
CKD Management:
- Renal protective: ACEI + SGLT2i (Dapagliflozin - DAPA-CKD trial, reduces CKD progression + CV events)
- Erythropoietin stimulating agents (ESA) + IV iron if Hb <10 g/dL
- Avoid nephrotoxins: NSAIDs, contrast (nephrotoxic), aminoglycosides
- Renal diet: low potassium, low phosphate, adequate protein
- Dialysis if indicated (uremic symptoms, uncontrolled electrolytes, fluid overload refractory to diuretics)
VIVA Q&A
Q1. This patient has CAD + CKD with pleural effusion. How do you decide if the effusion is cardiac or renal?
A: Both are transudates. Clinical approach: (1) BNP/NT-proBNP - markedly elevated (>500 pg/mL) favors cardiac; (2) Echo - LV dysfunction favors cardiac origin; (3) Serum albumin - if very low (<2 g/dL), nephrotic contribution; (4) Effusion pattern - CCF typically bilateral right-sided; nephrotic often bilateral; (5) Treatment response - if effusion resolves with diuresis and cardiac management, confirms cardiac origin.
Q2. What is Cardiorenal Syndrome Type 2?
A: Chronic heart failure leading to progressive CKD. Mechanism: reduced cardiac output → reduced renal perfusion → RAAS activation → renal vasoconstriction → GFR reduction; venous congestion increases renal venous pressure reducing filtration gradient. Treatment: optimize cardiac output (ACE inhibitor, diuretics, CRT if dyssynchrony) while protecting kidneys (avoid nephrotoxins, SGLT2i).
Q3. What is the SERAPH/SAAG (Serum-Ascites/Serum-Pleural Albumin Gradient) for distinguishing transudate?
A: Serum albumin - pleural fluid albumin difference >1.2 g/dL = TRANSUDATE (portal hypertension/cardiac mechanism). Difference <1.2 g/dL = EXUDATE. This is more specific than Light's criteria (especially when diuretics have been given, which can artificially elevate pleural protein making transudate appear as exudate by Light's criteria). Sensitivity for transudate: 97%, specificity: 80%.
Q4. Why is diuresis first-line and not thoracocentesis for CCF effusion?
A: CCF effusions are transudates - draining the fluid provides only temporary relief as the underlying increased hydrostatic pressure (cardiac failure) will re-accumulate the effusion rapidly. Diuresis addresses the root cause by reducing total body volume and venous pressures. Thoracocentesis is reserved for: tense/tension effusion causing hemodynamic compromise, diagnostic uncertainty, failure to respond to diuretics.
Q5. What is the Light's criteria limitation in CCF patients on diuretics?
A: Diuretics cause preferential concentration of proteins in pleural fluid (fluid is absorbed faster than proteins) → pleural protein/LDH rises → transudate misclassified as exudate by Light's criteria (in up to 25% of CCF patients on diuretics). Solution: use Serum-Pleural Albumin Gradient (SPAG) > 1.2 g/dL = confirms transudate even if Light's criteria says exudate. Also: NT-proBNP in pleural fluid >1500 pg/mL = cardiac effusion.
MASTER SHORT CASE REFERENCE - ALL 5 RS CASES
| # | Patient | Diagnosis | Key Finding | Trachea | Percussion | BS | Added Sounds | Clubbing | Top Viva Point |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sadayanthi 70/M | Bronchiectasis + Old PTB + HFrEF 30% | Fine crepts R upper + B/L wheeze | Central | Dull R upper | Reduced R upper | Fine crepts + wheeze | Grade 3 | HFrEF quadruple therapy; azithromycin in bronchiectasis |
| 2 | Chinna Ponnu | AECOPD + Consolidations + Old PTB | L>R BBS | Central | Dull bilateral lower | L>R Bronchial | Coarse crepts, wheeze | Absent | SpO2 target 88-92%; NIV if pH <7.35 |
| 3 | Aruldoss (B/U) | Right Pneumonia + Clubbing | R IA/IM BBS + crepts | Central | Dull R lower | R Bronchial | Crepts, rub | Present | Air bronchogram; CURB-65; clubbing = pre-existing disease |
| 4 | Ravi 62/M (B/U) | L Fibrothorax + s/p AVR + SHTN | B/L supraclavicular hollowing, absent L BS | Right | Stony dull L | Absent L | Nil | Absent | Fibrothorax vs effusion; prosthetic valve assessment; INR 2.5-3.5 |
| 5 | Anadharaj (B/U) | R Effusion + Vol overload + CAD + CKD | R decreased AE + edema + raised JVP | Left | Stony dull R | Absent R | Fine basal crepts | Absent | SPAG >1.2 = transudate; diuresis first not thoracocentesis; cardiorenal syndrome |
This is a shared conversation. Sign in to Orris to start your own chat.